Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons

Stem Cells

Volumn 31, Issue 8, 2013, Pages 1548-1562

  Sundberg, Maria ^a   Bogetofte, Helle ^a   Lawson, Tristan ^a   Jansson, Johan ^a   Smith, Gaynor ^a   Astradsson, Arnar ^a   Moore, Michele ^a   Osborn, Teresia ^a   Cooper, Oliver ^a   Spealman, Roger ^a   Hallett, Penelope ^a   Isacson, Ole ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Differentiation; Embryonic stem cells; Flow cytometry; Induced pluripotent stem cells; Neural differentiation; Parkinson's disease; Transplantation; Xenotransplantation

Indexed keywords

BETA1 INTEGRIN; HEPATOCYTE NUCLEAR FACTOR 3BETA; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; NUCLEAR RECEPTOR RELATED FACTOR 1; OXIDOPAMINE; PROTEIN; PROTEIN EN1; PROTEIN GIRK2; PROTEIN LMX1A; PROTEIN TH; TRANSCRIPTION FACTOR OTX2; TRANSCRIPTION FACTOR PITX3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN TISSUE; CELL SUBPOPULATION; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; ENGRAFTMENT; FEASIBILITY STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; INNERVATION; MACACA; MALE; MOTOR PERFORMANCE; NERVE CELL DIFFERENTIATION; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; RAT; SAFETY;

DIFFERENTIATION; EMBRYONIC STEM CELLS; FLOW CYTOMETRY; INDUCED PLURIPOTENT STEM CELLS; NEURAL DIFFERENTIATION; PARKINSON'S DISEASE; TRANSPLANTATION; XENOTRANSPLANTATION;

ADULT; ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; EMBRYONIC STEM CELLS; FEMALE; GENE EXPRESSION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MACACA FASCICULARIS; MALE; NEURONS; PARKINSON DISEASE; PLURIPOTENT STEM CELLS; RANDOM ALLOCATION; RATS; STEM CELL TRANSPLANTATION;

EID: 84883431348     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1415     Document Type: Article

References (51)

1. Ma Y, Tang C, Chaly T et al. Dopamine cell implantation in Parkinson's disease: Long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med 2010;51:7-15.
2. Politis M, Wu K, Loane C et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Science Transl Med 2010;2:38ra46.
3. Kirkeby A, Grealish S, Wolf DA et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Reports 2012;1:703-714.
4. Kriks S, Shim JW, Piao J et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011;480:547-551.
5. Xi J, Liu Y, Liu H et al. Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem Cells 2012;30: 1655-1663.
6. Ono Y, Nakatani T, Sakamoto Y et al. Differences in neurogenic potential in floor plate cells along an anteroposterior location: Midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 2007;134:3213-3225.
7. Hynes M, Porter JA, Chiang C et al. Induction of midbrain dopaminergic neurons by Sonic hedgehog. Neuron 1995;15:35-44.
8. Prakash N, Brodski C, Naserke T et al. A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development 2006;133:89-98.
9. Ye W, Shimamura K, Rubenstein JL et al. FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 1998;93:755-766.
10. Cooper O, Hargus G, Deleidi M et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci 2010;45:258-266.
11. Doi D, Morizane A, Kikuchi T et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 2012;30:935-945.
12. Sonntag KC, Pruszak J, Yoshizaki T et al. Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 2007;25:411-418.
13. Brederlau A, Correia AS, Anisimov SV et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: Effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006;24:1433-1440.
14. Pruszak J, Ludwig W, Blak A et al. CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem cells 2009;27:2928-2940.
15. Sundberg M, Jansson L, Ketolainen J et al. CD marker expression profiles of human embryonic stem cells and their neural derivatives, determined using flow-cytometric analysis, reveal a novel CD marker for exclusion of pluripotent stem cells. Stem Cell Res 2009;2: 113-124.
16. Yuan SH, Martin J, Elia J et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. Plos One 2011;6:e17540.
17. Ganat YM, Calder EL, Kriks S et al. Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. J Clin Investig 2012;122:2928-2939.
18. Hedlund E, Pruszak J, Lardaro T et al. Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 2008;26: 1526-1536.
19. Cooper O, Seo H, Andrabi S et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012;4:141ra190.
20. Deleidi M, Hargus G, Hallett P et al. Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. Stem Cells 2011;29:1052-1063.
21. Chambers SM, Fasano CA, Papapetrou EP et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27:275-280.
22. Pruszak J, Sonntag KC, Aung MH et al. Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 2007;25:2257-2268.
23. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968;5:107-110.
24. Debeir T, Ginestet L, Francois C et al. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp Neurol 2005;193:444-454.
25. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002;175:303-317.
26. Hargus G, Cooper O, Deleidi M et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA 2010;107:15921-15926.
27. Astradsson A, Jenkins BG, Choi JK et al. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates - Evidence from in vivo neuroimaging studies. Neurobiol Dis 2009;35: 348-351.
28. Sanchez-Pernaute R, Studer L, Ferrari D et al. Long-term survival of dopamine neurons derived from parthenogenetic primate embryonic stem cells (cyno-1) after transplantation. Stem Cells 2005;23:914-922.
29. Mann TM, Williams KE, Pearce PC et al. A novel method for activity monitoring in small non-human primates. Lab Anim 2005;39: 169-177.
30. Fasano CA, Chambers SM, Lee G et al. Efficient derivation of functional floor plate tissue from human embryonic stem cells. Cell Stem cell 2010;6:336-347.
31. Kataoka H, Takakura N, Nishikawa S et al. Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev Growth Differ 1997;39:729-740.
32. Fujiwara M, Yan P, Otsuji TG et al. Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. Plos One 2011;6:e16734.
33. Mendez I, Sanchez-Pernaute R, Cooper O et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005; 128(pt 7):1498-1510.
34. Schultzberg M, Dunnett SB, Bjorklund A et al. Dopamine and cholecystokinin immunoreactive neurons in mesencephalic grafts reinnervating the neostriatum: Evidence for selective growth regulation. Neuroscience 1984;12:17-32.
35. Thompson L, Barraud P, Andersson E et al. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci 2005;25: 6467-6477.
36. Herbert J, Cavallaro T, Dwork AJ. A marker for primary choroid plexus neoplasms. Am J Pathol 1990;136:1317-1325.
37. Lappalainen RS, Salomaki M, Yla-Outinen L et al. Similarly derived and cultured hESC lines show variation in their developmental potential towards neuronal cells in long-term culture. Regen Med 2010;5: 749-762.
38. Bjorklund LM, Sanchez-Pernaute R, Chung S et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002;99: 2344-2349.
39. Sundberg M, Andersson PH, Akesson E et al. Markers of pluripotency and differentiation in human neural precursor cells derived from embryonic stem cells and CNS tissue. Cell Transplant 2011;20: 177-191.
40. Emborg ME, Zhang Z, Joers V, Brunner K, Bondarenko V, Ohshima S, Zhang SC. Intracerebral transplantation of differentiated human embryonic stem cells to Hemiparkinsonian monkeys. Cell Transplantation 2013;22:831-838.
41. Cicchetti F, Fodor W, Deacon TW et al. Immune parameters relevant to neural xenograft survival in the primate brain. Xenotransplantation 2003;10:41-49.
42. Kim K, Doi A, Wen B et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010;467:285-290.
43. Parker GC, Acsadi G, Brenner CA. Mitochondria: Determinants of stem cell fate? Stem Cells Dev 2009;18:803-806.
44. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317.
45. Ahrlund-Richter L, De Luca M, Marshak DR et al. Isolation and production of cells suitable for human therapy: Challenges ahead. Cell Stem cell 2009;4:20-26.
46. Zhao T, Zhang ZN, Rong Z et al. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212-215.
47. Kaji K, Norrby K, Paca A et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458: 771-775.
48. Woltjen K, Michael IP, Mohseni P et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458: 766-770.
49. Soldner F, Hockemeyer D, Beard C et al. Parkinson's disease patientderived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-977.
50. Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324: 797-801.
51. Zhou H, Wu S, Joo JY et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem cell 2009;4:381-384.